文献速递医院感染防控细菌感染、耐药与抗菌药物新发突发、热带与寄生虫病

免疫功能受损人群主动与被动免疫的创新:行动呼吁

Innovation in active and passive immunisation of people who are immunocompromised: a call to action.
PubMed 文献 · Lancet Infect Dis · 2025-08-11

本文指出免疫功能受损人群比例持续增长且感染并发症风险升高,同时已知和新发病原体暴发增加。疫苗是感染预防的基础,但该类人群免疫应答减弱,需在设计和服务策略上创新;被动免疫可短暂直接转移免疫力,对无法产生强免疫应答者有价值,但现有疗法不足。本文围绕疫苗学、单克隆抗体设计、研究终点、卫生系统方法和政策考量讨论关键未满足需求。

要点

  • 免疫功能受损人群感染并发症风险升高,疫苗应答减弱,需创新主动与被动免疫策略。
  • 被动免疫可短暂直接转移免疫力,对无法产生强免疫应答者有价值,但现有疗法不足。
  • 需在疫苗学、单克隆抗体设计、研究终点、卫生系统与政策层面回应未满足需求。

核心结论

  • 免疫功能受损人群的主动与被动免疫需要设计和实施策略的创新,现有被动免疫疗法仍不足。

研究设计与样本

  • 本文为系列论文,围绕疫苗学、单克隆抗体设计、研究终点、卫生系统方法和政策考量讨论关键未满足需求。

主要发现

  • 免疫功能受损人群比例持续增长,感染并发症风险升高。
  • 已知和新发病原体暴发增加。
  • 疫苗是感染预防的基础,但免疫功能受损者减弱的免疫应答需要创新设计与实施策略。
  • 被动免疫可将所需免疫力直接转移给个体 albeit 短暂,对无法通过疫苗或感染产生强免疫应答者可能有价值。
  • 免疫学技术与概念进展为预防和治疗感染性疾病的新策略与新疗法创造机会,免疫功能受损人群是重要应用场景。

临床怎么用

  • 临床应关注免疫功能受损人群的感染预防,重视疫苗应答减弱问题并考虑被动免疫等替代策略。
  • 在疫苗和单克隆抗体研发与应用中,应纳入免疫功能受损人群作为重要研究对象和适用人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The proportion of the population with immunocompromising conditions, who are at increased risk for complications from infectious diseases, continues to grow. Concurrently, outbreaks due to known and emerging pathogens are increasing. Vaccines are the foundation of infection prevention; however, attenuated immune responses in people who are immunocompromised necessitates innovation in design and delivery strategies. Passive immunisation, whereby the desired immunity is directly transferred to an individual, albeit transiently, could be valuable for patients who are unable to generate robust immune responses with vaccination or infection. However, existing therapies are insufficient. Considerable technical and conceptual advancements in the field of immunology have created unprecedented opportunities for the development of novel strategies and therapies to prevent and treat infectious diseases, and studies in people who are immunocompromised are an important setting in which to apply these developments. In this Series paper, we consider key unmet needs in the areas of vaccinology, monoclonal antibody design, study endpoints, health systems approaches, and policy considerations for people who are immunocompromised.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Hill JA, Boonyaratanakornkit J, Mikulska M, et al. Innovation in active and passive immunisation of people who are immunocompromised: a call to action. Lancet Infect Dis. 2025. PMID: 40812340. doi:10.1016/S1473-3099(25)00345-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。